Truist Financial Lowers Globus Medical (NYSE:GMED) Price Target to $100.00

Globus Medical (NYSE:GMED) had its price target cut by analysts at Truist Financial from $115.00 to $100.00 in a research report issued on Thursday, MarketBeat reports. The brokerage currently has a “buy” rating on the medical device company’s stock. Truist Financial’s price target indicates a potential upside of 29.86% from the stock’s current price.

GMED has been the topic of several other reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a report on Monday. Zacks Research cut Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Wells Fargo & Company cut their price objective on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Piper Sandler reduced their target price on Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a research note on Monday, June 15th. Finally, Needham & Company LLC lifted their target price on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Globus Medical presently has a consensus rating of “Moderate Buy” and an average target price of $103.75.

Globus Medical Trading Down 4.8%

GMED stock opened at $77.01 on Thursday. The stock has a market cap of $10.45 billion, a PE ratio of 17.91, a P/E/G ratio of 1.67 and a beta of 0.95. Globus Medical has a 12 month low of $51.79 and a 12 month high of $101.40. The company has a 50-day moving average price of $79.84 and a 200 day moving average price of $86.47.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Sell-side analysts forecast that Globus Medical will post 4.74 EPS for the current year.

Insider Buying and Selling at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the sale, the director owned 510,175 shares in the company, valued at approximately $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 18.38% of the company’s stock.

Institutional Investors Weigh In On Globus Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Elevation Wealth Partners LLC increased its stake in shares of Globus Medical by 2,178.6% during the second quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock valued at $25,000 after buying an additional 305 shares during the period. Advisory Services Network LLC purchased a new stake in Globus Medical in the third quarter worth about $26,000. EverSource Wealth Advisors LLC lifted its stake in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after acquiring an additional 197 shares during the period. SBI Securities Co. Ltd. lifted its stake in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares during the period. Finally, Parallel Advisors LLC grew its holdings in Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after acquiring an additional 173 shares in the last quarter. 95.16% of the stock is owned by institutional investors.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: GMED’s one-year rally has been attributed to strong growth in both business segments, rising technology adoption, and a debt-free balance sheet, reinforcing confidence in the company’s operating momentum. GMED Stock Surges 43.6% in a Year: What’s Driving the Rally?
• Positive Sentiment: Wall Street still appears constructive on Globus Medical, with Truist reiterating a buy rating even after lowering its price target to $100, which still implies meaningful upside from recent levels. Globus Medical (NYSE:GMED) Price Target Lowered to $100.00 at Truist Financial
• Positive Sentiment: Recent commentary also says GMED still looks undervalued after its recent gains, which may be attracting value-oriented investors. Globus Medical (GMED) Stock Still Looks Undervalued Despite A 39% Return
• Positive Sentiment: Zacks highlighted GMED as a strong value stock, supporting the view that the shares may still have room to run if fundamentals remain solid. Here’s Why Globus Medical (GMED) is a Strong Value Stock
• Neutral Sentiment: The company scheduled its second-quarter 2026 earnings release for August 6, which keeps investors focused on upcoming results and guidance, but does not by itself change the investment thesis. Globus Medical Schedules Second Quarter Earnings Release and Conference Call
• Neutral Sentiment: Globus Medical also announced it will host a conference call to discuss second-quarter results, increasing visibility into the business ahead of earnings. Globus Medical to Announce Second Quarter 2026 Financial Results on August 6
• Negative Sentiment: A shareholder litigation firm said it is investigating possible fiduciary-duty breaches by certain officers and directors, which could create overhang and governance concerns for GMED. Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.